Clinical Trial

A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase II study to investigate the safety, preliminary efficacy and pharmacokinetics of SC0062 capsule in patients with chronic kidney disease (diabetic kidney disease and IgA nephropathy)with albuminuria compared to matching placebo.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-01-09; most recent amendment 2025-01-06.
Status change: Recruiting → Active, Not Recruiting 2024-09-23
Status change: Not Yet Recruiting → Recruiting 2023-07-24
Trial Details
NCT Number NCT05687890
Lead Sponsor Biocity Biopharmaceutics Co., Ltd.
Conditions Diabetic Kidney Disease, IgA Nephropathy
Enrollment 255 participants
Start Date 2023-05-23
Primary Completion 2024-11-30 (estimated)
Study Completion 2025-04 (estimated)
Updated on ClinicalTrials.gov 2025-01-07